Marshall Wace, LLP Esperion Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 3,092,629 shares of ESPR stock, worth $9.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,092,629

Previous 4,303,596 28.14%

Holding current value

$9.59 Million

Previous $9.55 Million 46.59%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.73 $1.95 Million - $3.31 Million	-1,210,967 Reduced 28.14%	3,092,629 $5.1 Million
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $3.84 Million - $6.76 Million	2,087,635 Added 94.21%	4,303,596 $9.55 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $3.55 Million - $5.31 Million	1,758,203 Added 384.09%	2,215,961 $5.94 Million
Q4 2023 Feb 14, 2024	SELL	$0.73 - $3.08 $814,955 - $3.44 Million	-1,116,378 Reduced 70.92%	457,758 $1.37 Million
Q3 2023 Nov 14, 2023	BUY	$0.96 - $1.79 $1.21 Million - $2.25 Million	1,258,207 Added 398.26%	1,574,136 $1.54 Million
Q2 2023 Aug 14, 2023	BUY	$1.2 - $1.76 $33,988 - $49,850	28,324 Added 9.85%	315,929 $439,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $164,369 - $821,848	112,582 Added 64.32%	287,605 $457,000
Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $1.96 Million - $3.28 Million	-385,964 Reduced 68.8%	175,023 $1.09 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $2.91 Million - $4.34 Million	534,387 Added 2008.97%	560,987 $3.76 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $126,881 - $177,422	26,600 New	26,600 $169,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $2.5 Million - $6.2 Million	-520,095 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $7.39 Million - $13.9 Million	-651,975 Reduced 55.63%	520,095 $6.27 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $28.71 $2.76 Million - $4.09 Million	142,369 Added 13.83%	1,172,070 $24.8 Million
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $8.7 Million - $12.8 Million	-346,229 Reduced 25.16%	1,029,701 $28.9 Million
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $237,765 - $351,342	9,825 Added 0.72%	1,375,930 $35.8 Million
Q3 2020 Nov 16, 2020	BUY	$31.18 - $52.71 $2.35 Million - $3.97 Million	75,331 Added 5.84%	1,366,105 $50.8 Million
Q2 2020 Aug 13, 2020	SELL	$30.04 - $51.31 $996,516 - $1.7 Million	-33,173 Reduced 2.51%	1,290,774 $66.2 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $36.3 Million - $97.8 Million	1,323,947 New	1,323,947 $41.7 Million
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $185,863 - $242,549	-4,635 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$40.11 - $53.57 $185,909 - $248,296	4,635 New	4,635 $186,000

Others Institutions Holding ESPR

# of Institutions

207

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $206M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Esperion Therapeutics, Inc. Transaction History